Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
GLP-1 RAs STEP 1 (2021) : Semaglutide 2.4 ./ 14.9% 68 2.4% (Wilding et al., 2021, NEJM) SURMOUNT-1 (2022) : Tirzepatide (GLP-1/GIP dual agonist) 15 ./ 20.9% (Jastreboff et al., 2022, NEJM) GLP-1 HbA1c () 2 (Hypoglycemia) Glucose-dependent LEADER (liraglutide) SUSTAIN-6 (semaglutide) 2024 FDA Semaglutide (Wegovy) FLOW (2024) semaglutide (MASLD/NAFLD) GLP-1 RAs GLP-1
B12 injections bypass some of the potential barriers to absorption so can be very helpful especially in patients with digestive concerns or pill fatigue
Key Takeaways GLP-1 microdosing is a rapidly growing practice that sits in a gray area between established medicine and emerging trend
The guiding principle is to find the lowest effective dose that comfortably sustains continued outcomes for the long term, rather than rushing everyone to the maximum dose in the minimum time
Clinical Trial Results: The Numbers That Matter The Phase 2 clinical trial published in the New England Journal of Medicine provided the foundational data driving interest in Retatrutide
For T1DM patients, insulin replacement is essential due to insufficient endogenous insulin secretion
,aspect=ignore)
